x

Posted 03 August, 2022

AVENUE THERAPEUTICS, INC. appointed Alexandra MacLean as new CEO

Nasdaq:ATXI appointed new Chief Executive Officer Alexandra MacLean in a 8-K filed on 03 August, 2022.


  On August 1, 2022, the Board of Directors of Avenue Therapeutics, Inc. (the "Company") appointed Alexandra MacLean, M.D., to serve as the Company's Chief Executive Officer, with immediate effect.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of AVENUE THERAPEUTICS, INC.
Health Care/Life Sciences • Pharmaceuticals
Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in Bay Harbor Islands, FL.
Market Cap
$2.05M
View Company Details
AVENUE THERAPEUTICS, INC. by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


On August 1, 2022, the Board of Directors of Avenue Therapeutics, Inc. (the "Company") appointed Alexandra MacLean, M.D., to serve as the Company's Chief Executive Officer, with immediate effect.


Dr. MacLean, 55, previously served as Entrepreneur in Residence at Fortress Biotech, Inc. (NASDAQ: FBIO), a biopharmaceutical company and a partner company of the Company, from November 2021 through July 2022. She previously served as General Partner and Principal at TVM Capital GmbH, an international life sciences venture capital firm, from January 2020 through October 2021; as Head of Licensing and Business Development at Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and a subsidiary of Purdue Pharma, L.P. ("Purdue"), from January 2019 through January 2020; and in various roles at Purdue, a privately held pharmaceutical company, from 2015 to January 2019. Prior to joining Purdue, she served at Plasma Surgical, Inc., a medical device company, from 2014 to 2015, and Covidien, a medical devices and supplies manufacturer later acquired by Medtronic plc (NYSE: MDT), from 2010 to 2013. She began her career in the pharmaceutical industry at Merck & Co. (NYSE: MRK), a pharmaceutical company, where she worked from 2008 to 2010. Dr. MacLean holds an M.D. degree from Columbia University, Vagelos College of Physicians and Surgeons, an MBA from the University of Colorado - Boulder, and an M.Phil. from the University of Cambridge in History of Science. She obtained a B.Sc. in Physiology from McGill University.


There are no family relationships between Dr. MacLean and any directors or executive officers of the company. Additionally, there are no arrangements between Dr. MacLean and any other person pursuant to which she was appointed as an executive officer. There have been no transactions in which the Company has participated and in which Dr. MacLean had a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation S-K.


Dr. MacLean does not currently have an employment agreement with the Company but will receive a cash salary in the amount of $332,200 per year.


With the appointment of Dr. MacLean as the new Chief Executive Officer, Mr. David Jin will end his term as interim Chief Executive Officer and will continue his responsibilities as Interim Chief Financial Officer and Chief Operating Officer of the Company.